Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
ClearPoint Neuro, Inc. CLPT
$9.04
-$0.06 (-0.66%)
На 18:02, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
229352859.00000000
-
week52high
16.96
-
week52low
7.00
-
Revenue
20551000
-
P/E TTM
-14
-
Beta
1.13633200
-
EPS
-0.61000000
-
Last Dividend
0.00000000
-
Next Earnings Date
11 мая 2023 г. в 20:00
Описание компании
ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. The company develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under direct, and intra-procedural magnetic resonance imaging (MRI) guidance. It offers ClearPoint system for the insertion of deep brain stimulation electrodes and biopsy needles, and the infusion of pharmaceuticals and laser catheters into the brain; and ClearPoint Neuro Navigation System, an MRI suite. It has license and collaboration agreements with Boston Scientific Corporation, The Johns Hopkins University, Clinical Laserthermia Systems Americas Inc, Koninklijke Philips N.V., Blackrock Neurotech, and University of California and San Francisco. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Lake Street | Buy | 18 мар 2021 г. | |
| B. Riley FBR | Buy | Buy | 17 июл 2020 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| JOHNSON B KRISTINE | A | 20453 | 431 | 03 янв 2023 г. |
| FLETCHER R JOHN | A | 70461 | 2175 | 03 янв 2023 г. |
| Girin Pascal E R | A | 49653 | 901 | 03 янв 2023 г. |
| Richards Timothy T. | A | 36038 | 1399 | 03 янв 2023 г. |
| D'Alessandro Danilo | A | 54729 | 1252 | 30 дек 2022 г. |
| STIGALL L. JEREMY | A | 43420 | 728 | 30 дек 2022 г. |
| SABRA MAZIN | A | 46900 | 46000 | 10 окт 2022 г. |
| JOHNSON B KRISTINE | A | 20022 | 337 | 03 окт 2022 г. |
| Girin Pascal E R | A | 48752 | 705 | 03 окт 2022 г. |
| FLETCHER R JOHN | A | 68286 | 1702 | 03 окт 2022 г. |
Новостная лента
ClearPoint Neuro Is A 'Buy' Based On Growing Revenues And Decreasing Cash Burn
Seeking Alpha
30 янв 2023 г. в 01:30
ClearPoint Neuro is a growth story and should be evaluated as such. I break down some of the growth factors that I consider most important.
ClearPoint Neuro to Present at Upcoming Investor Conferences
GlobeNewsWire
09 ноя 2022 г. в 09:25
SOLANA BEACH, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, announced today that its management will present at the following investor conferences:
ClearPoint Neuro, Inc. (CLPT) Reports Q3 Loss, Misses Revenue Estimates
Zacks Investment Research
08 ноя 2022 г. в 20:18
ClearPoint Neuro, Inc. (CLPT) delivered earnings and revenue surprises of 21.05% and 6.61%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
ClearPoint Neuro, Inc. (CLPT) Q3 2022 Earnings Call Transcript
Seeking Alpha
08 ноя 2022 г. в 18:15
ClearPoint Neuro, Inc. (NASDAQ:CLPT ) Q3 2022 Earnings Conference Call November 8, 2022 4:30 PM ET Company Participants Joe Burnett - CEO Danilo D'Alessandro - CFO Conference Call Participants William Wood - B. Riley Frank Takkinen - Lake Street Capital Operator Greetings, and welcome to the ClearPoint Neuro, Inc. Third Quarter 2022 Financial Results Conference Call.
ClearPoint Neuro: Continuous Great Execution
Seeking Alpha
19 сент 2022 г. в 12:56
Revenue growth rebounded strongly due to its acceleration in B&DD and capital equipment and software revenue. The company marks its first milestone with its FDA approval with PTC-AADC, with certainly more to come.